Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

Pharmala Biotech Holdings  / Equity Bottom-Up

<ul><li>Restora Neurosciences SPV housing APA-01. PharmAla entered a definitive agreement with CRO Diteba and its parent company Aluvaris through the formation of Restora Neurosciences, a 50/50 Special Purpose Vehicle (SPV) with Aluvaris and Diteba to develop its patented non-controlled molecule, APA-01. </li><li>Under the terms of the agreement, PharmAla contributes the preclinical asset and global IP, Aluvaris funds the vehicle by raising a ~$2.5-million threshold, and Diteba runs the bioanalytical and IND work.</li><li>The SPV must file its first IND within 36 months of funding, with failure reverting the IP to PharmAla. </li></ul>

Restora Neurosciences SPV housing APA-01. PharmAla entered a definitive agreement with CRO Diteba and its parent company Aluvaris through the formation of Restora Neurosciences, a 50/50 Special Purpose Vehicle (SPV) with Aluvaris and Diteba to develop its patented non-controlled molecule, APA-01. Under the terms of the agreement, PharmAla contributes the preclinical asset and global IP, Aluvaris funds the vehicle by raising a ~$2.5-million threshold, and Diteba runs the bioanalytical and IND work.The SPV must file its first IND within 36 months of funding, with failure reverting the IP to PharmAla. 

PharmAla Biotech Holding: The Pathway to Unlocking Pipeline Value Early